Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders

Toshihiro Kanaitsuka, Yuziro Namba, Youli Zu, Kazuhiro Ishii, Tsukasa Ashihara, Masao Hanaoka, Taizan Suchi

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We investigated the expression of fos oncogene proteins in lymphoproliferative disorders, using a monoclonal antibody (FO-120) that was prepared against a synthetic oligopeptide of fos protein (amino acid sequence from 127 to 152). Although peripheral blood leukocytes were rarely positive for FO-120, they were transiently stained after lectin (PHA) stimulation. After culture with IL-2 for 1 or 2 weeks, less than 40% of the lymphocytes weakly reacted with FO-120, whereas strongly positive cells were detected in more than 70% of cells in half the T-cell lines established from preleukemic state of adult T-cell leukemia (pre-ATL) and all of ATL derived T-cell lines. All in vivo specimens of non-Hodgkin's malignant lymphomas, except for one case of T-cell lymphoma were also strongly positive. In addition, the extent of the antibody reactivity correlated with the histopathological grade of malignancy in B-cell lymphoma. The reactivity to most of AILD-IBL lesions overlapped with that to T-lymphomas, and could be distinguished from that to reactive lesions. FO-120 appears to be a useful tool for detecting early neoplastic changes in lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)1025-1033
Number of pages9
JournalLeukemia Research
Volume13
Issue number11
DOIs
StatePublished - 1989

Keywords

  • Immunohistochemistry
  • adult T-cell leukemia/lymphoma
  • angioimmunoblastic lymphadenopathy
  • fos oncogene products
  • monoclonal antibody
  • non-Hodgkin's lymphoma
  • preleukemia
  • subacute necrotizing lymphadenitis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders'. Together they form a unique fingerprint.

Cite this